Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
first-in-class treatment for children and adults with classic congenital adrenal hyperplasia (CAH). CRENESSITY is an oral medication that reduces excess adrenal androgens and allows for lower doses of glucocorticoids, which can help alleviate symptoms of CAH and reduce the risk of long-term complications. The approval is based on data from the largest-ever clinical trial program in pediatric and adult patients with classic CAH, which showed that CRENESSITY was effective in reducing androgen levels and enabling lower glucocorticoid doses. CRENESSITY is expected to be commercially available in approximately one week and will be provided through a specialty pharmacy. Generated by Yahoo Finance AI Yahoo Finance used generative AI to summarize key information from this article. Some details may be inaccurate. We take that seriously. Reporting mistakes helps us improve these summaries. Was this helpful? Yes No CRENESSITY, the first new treatment available in 70 years to the clas
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal HyperplasiaPR Newswire
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $148.00 price target on the stock.MarketBeat
NBIX
Earnings
- 10/30/24 - Beat
NBIX
Sec Filings
- 12/20/24 - Form 8-K
- 12/19/24 - Form 4
- 12/19/24 - Form 4
- NBIX's page on the SEC website